Resveratrol 98% (CAS 501-36-0) — Product Description

Document scope: Bulk ingredient specification and compliance summary
Basis: Cross-referenced against GuideChem, ChemicalBook, Sigma-Aldrich, PubChem, Made-in-China, and Alibaba listings. Discrepancies corrected.

1. Product Identity

Isomer note: The 98% specification refers to trans-resveratrol. Cis-resveratrol may be present as a minor impurity or degradation product. Prolonged exposure to light and heat promotes trans-to-cis isomerization; specify isomer ratio on COA where relevant.

2. Key Quality Attributes

3. Regulatory and Compliance Status

United States: Resveratrol is not FDA-approved as a drug for any indication. It is marketed as a dietary supplement ingredient subject to 21 CFR Part 111 cGMP. GRAS status has been claimed for certain resveratrol ingredients in specified food applications, but GRAS status is ingredient- and use-level-specific; buyers must verify the supplier's GRAS basis rather than assuming blanket coverage. Importers are subject to FSVP requirements.

European Union: Bulk material placed on the EU market at ≥1 tonne/year requires REACH registration (EC) No 1907/2006. Cosmetic use requires safety assessment and CPNP notification under (EC) No 1223/2009. No novel food authorization exists for resveratrol as a food ingredient in the EU; suppliers should clarify the intended regulatory pathway before shipment.

China: Domestic suppliers position material as food-grade, cosmetic-grade, or pharmaceutical intermediate. Export documentation should match the destination market's intended use category.

Safety data (SDS-referenced): Oral LD50 in mouse >10,000 mg/kg (OECD 423) and >15,000 mg/kg (OECD 401); not a skin irritant or sensitizer in animal studies; Ames test negative. These data support handling under standard industrial hygiene practices, not as a hazardous substance requiring special transport classification.

4. Functional and Biological Profile

Resveratrol is a non-flavonoid polyphenolic phytoalexin produced by plants in response to stress or infection. In preclinical research it has been reported to exhibit antioxidant, anti-inflammatory, and cardiovascular-related activities, with proposed mechanisms including SIRT1 pathway modulation and inhibition of COX-1. Epidemiological associations between resveratrol intake and reduced cardiovascular risk have been suggested, but causal relationships in humans remain unestablished.

Positioning note: Commercial descriptions must not claim therapeutic efficacy for any disease. The ingredient is sold as a bulk raw material for further formulation, not as a drug. Structure/function claims for dietary supplement use must comply with applicable FDA labeling requirements and avoid disease language.

5. Supply Chain and Packaging

6. Purchasing Checklist

1. Confirm botanical vs. fermentation origin and request source documentation.

2. Request lot-specific HPLC chromatogram with integration data; verify trans-resveratrol content and cis-isomer level.

3. Confirm storage history from supplier; material stored at ambient temperature for extended periods may show isomerization or potency loss.

4. Request SDS and toxicological summary for handling and downstream regulatory submissions.

5. Verify regulatory alignment with intended market (US dietary supplement, EU cosmetic, or research use).

6. Check packaging light/moisture barrier and stability data supporting the stated shelf life in the proposed packaging configuration.